GUARDIAN PHARMACY SV A (GRDN) is drawing unusual attention today. Our newswire has captured 2 stories on GRDN across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Guardian Pharmacy Services stock surged 15.56% to $45.53 in a single session driven by strong second-quarter results and upgraded financial guidance. The company raised its 2026 revenue and EBITDA outlook after reporting improved profitability and growth in residents served. The stock opened with a 9.3% gap up and reached an intraday high of $45.80 before settling at $45.53.
Guardian Pharmacy Services (NYSE: GRDN) announced stronger-than-expected Q2 2026 financial results, including a non-GAAP EPS of $0.29, which beat estimates by $0.03. Revenue for the quarter reached $351.8 million, exceeding expectations by $11.35 million. The company also raised its FY2026 revenue guidance to a range of $1.43 billion to $1.45 billion from $1.4 billion to $1.42 billion. These updates reflect improved operational performance and a 13.5% year-to-date revenue increase. Additionally, Oppenheimer raised its price target for GRDN to $49 from $43, and Truist Securities increased its target to $47. The company also announced the appointment of CFO David Morris as COO and the acquisition of Wellness Concepts, though terms were not disclosed.
The stock opened at $43.15, a significant jump from the prior close of $39.47. It reached a session high of $45.80 at 9:40 AM ET before retreating slightly. The price trend shows a 52-week range of $19.30 to $44.00, with the current price near the upper end. The stock traded 0.0M shares so far, which is 0.1x the 3-month daily average. The market cap stands at $2.6 billion, with a P/E ratio of 47.2, reflecting strong investor optimism.
The company’s Q2 2026 earnings call transcript is available for further analysis, and investors may watch for additional guidance or strategic updates in the coming weeks. Coverage breadth and any further analyst revisions will also be key indicators of continued momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- In connection with the previously announced merger (the "Merger ") of Guardian i 3 Global Quality Growth ETF (TSX: GIQG, GIQG.B) (the "Merging Fund ") into Guardian...
Guardian Pharmacy Services (NYSE:GRDN) reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.
GUARDIAN PHARMACY SV A (GRDN) is drawing unusual attention today. Our newswire has captured 2 stories on GRDN across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100). The most recent driver: "Guardian Capital Announces Estimated Final Distributions for Merging Fund" (Business Insider).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GRDN coverage reads 53/100 over 2 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on GRDN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GRDN move explainers: 2026-08-07